Idiopathic Orthostatic Hypotension and other Autonomic Failure Syndromes Medication

  • Author: Mohini Gurme, MD; Chief Editor: Selim R Benbadis, MD   more...
 
Updated: Feb 3, 2012
 

Medication Summary

Several medications are available to help manage symptoms of autonomic dysfunction. The most commonly used are listed below.

Next

Mineralocorticoids

Class Summary

These agents play a role in hemodynamics and can be used to control orthostatic hypotension.

Fludrocortisone (Florinef)

 

Used to increase standing blood pressure. Acts to increase sodium retention and expand plasma volume.

Previous
Next

Alpha-adrenergic agonists

Class Summary

These agents improve the hemodynamic status by increasing myocardial contractility and heart rate, resulting in increased cardiac output. They also increase peripheral resistance by causing vasoconstriction. Increased cardiac output and increased peripheral resistance lead to increased blood pressure.

Midodrine (ProAmatine)

 

Alpha-adrenergic agonist used in orthostatic hypotension to increase standing blood pressure. Acts at level of resistance vessels and is useful for peripherally mediated hypotension.

Previous
Next

Beta-adrenergic blocking agents

Class Summary

These agents limit heart rate and reduce blood pressure.

Propranolol (Inderal)

 

Nonselective beta-blocker that is lipophilic (penetrates CNS).

Previous
Next

Vasopressors

Class Summary

These agents augment both coronary and cerebral blood flow that occurs during the low flow state associated idiopathic hypotension.

Desmopressin (DDAVP, Stimate)

 

Increases cellular permeability of collecting ducts, resulting in reabsorption of water by kidneys. Helpful for symptoms of nocturia.

Previous
Next

Erythropoietins

Class Summary

Anemia may occur due to low blood levels of endogenous erythropoietin, which can result from a lack of sympathetic innervation. Erythropoietins may also increase blood pressure through other mechanisms.

Epoetin alfa (Epogen, Procrit)

 

Stimulates RBC production in bone marrow. Increases sensitivity to pressor effects of angiotensin II, intravascular volume, cytosolic free calcium in vascular smooth muscle, and plasma endothelin level. Enhances renal tubular reabsorption.

Previous
Next

Gastroprokinetic agents

Class Summary

These agents promote motility of the GI tract.

Metoclopramide (Reglan)

 

Dopamine agonist helpful in relieving GI paresis.

Previous
Next

Anticholinesterase inhibitors

Class Summary

These agents inhibit acetylcholinesterase (AChE), raising the concentration of ACh at cholinergic synapses and increasing the chance of activating the AChR.

Pyridostigmine bromide (Mestinon)

 

Stimulates muscarinic AChR, increasing salivation and gastric motility.

Previous
Next

Bulk agents

Class Summary

Used for the chronic treatment of constipation.

Psyllium (Metamucil, Fiberall)

 

Must be taken with water or may cause obstruction. Increase dose gradually. Inform patient that effect not immediate.

Previous
Next

Antispasmodic agents

Class Summary

These agents may be helpful for urinary symptoms.

Oxybutynin (Ditropan)

 

Useful for urinary urgency. Inhibits action of ACh on smooth muscle and direct antispasmodic effect on smooth muscle, which increases bladder capacity and decreases uninhibited contractions.

Previous
Next

Cholinergic agents

Class Summary

These agents stimulate cholinergic receptors in the smooth muscle of the urinary bladder for stimulation of bladder emptying.

Bethanechol hydrochloride (Duvoid, Urecholine)

 

For selective stimulation of the bladder to produce contraction to initiate micturition and empty bladder. Most useful in bladder hypotonia. Rarely used because of GI stimulation and difficulty in timing effect.

Previous
Next

Phosphodiesterase inhibitors

Class Summary

These oral agents act peripherally to induce smooth muscle relaxation of the corpora cavernosa.

Sildenafil (Viagra)

 

Selective PDE5 inhibitor that inactivates cGMP, attenuating vasodilatory effect of NO. Effective in mild-to-moderate erectile dysfunction. Patient should take on an empty stomach about 1 h before sexual activity. Sexual stimulation necessary to activate response. Increased sensitivity for erections may last 24 h.

Previous
Next

Corticosteroids

Class Summary

These agents regulate key factors in the immune system.

Prednisone (Deltasone, Orasone, Meticorten)

 

Shorten duration of symptoms and improves overall prognosis in acute pandysautonomia.

Previous
Next

Immune globulins

Class Summary

These agents are used to improve clinical and immunologic aspects of the disease. May decrease autoantibody production, and increase solubilization and removal of immune complexes.

Immune globulins intravenous (IVIG, Gammagard, Gamimune)

 

Shortens duration of symptoms and improves overall prognosis in acute pandysautonomia. Clinical improvements have been reported within few days of administration, with normalization of autonomic parameters.

Neutralize circulating myelin antibodies through antiidiotypic antibodies; down-regulates proinflammatory cytokines, including INF-gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells and augments suppressor T cells; blocks complement cascade; promotes remyelination; may increase CSF IgG (10%).

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Mohini Gurme, MD  Resident Physician, Department of Neurology, University of California, Davis, School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Dianna Quan, MD  Associate Professor of Neurology, Director, Electromyography Laboratory, University of Colorado School of Medicine

Dianna Quan, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: e-medicine Honoraria Other

Bjorn E Oskarsson, MD  Assistant Professor, Department of Neurology, University of California Davis

Bjorn E Oskarsson, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Christopher Luzzio, MD  Clinical Assistant Professor, Department of Neurology, University of Wisconsin at Madison School of Medicine and Public Health

Christopher Luzzio, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Neil A Busis, MD  Chief, Division of Neurology, Department of Medicine, Head, Clinical Neurophysiology Laboratory, University of Pittsburgh Medical Center-Shadyside

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Jeffrey Tam Sing, MD to the development and writing of this article.

References
  1. Sithinamsuwan P, Orrawanhanothai P, Thithum K, Udommongkol C, Chairangsaris P, Chinvarun Y, et al. Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson's disease in Phramongkutklao Hospital. J Med Assoc Thai. Nov 2010;93 Suppl 6:S93-9. [Medline].

  2. Yu X, Stavrakis S, Hill MA, Huang S, Reim S, Li H, et al. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an "autoimmune" orthostatic hypotension. J Am Soc Hypertens. Jan-Feb 2012;6(1):40-7. [Medline]. [Full Text].

  3. Klein CM, Vernino S, Lennon VA, et al. The spectrum of autoimmune autonomic neuropathies. Ann Neurol. 2003;53:752-8. [Medline].

  4. Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol. Jan 2004;61(1):44-8. [Medline].

  5. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. Feb 1 1999;163(1):94-8. [Medline].

  6. Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol. Jul 2007;6(7):632-42. [Medline].

  7. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. Feb 7 2008;358(6):615-24. [Medline].

  8. Schroeder C, Vernino S, Birkenfeld AL, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. Oct 13 2005;353(15):1585-90. [Medline].

  9. Heafield MT, Gammage MD, Nightingale S, Williams AC. Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet. Jan 6 1996;347(8993):28-9. [Medline].

  10. Quan D, Rich MM, Bird SJ. Acute idiopathic dysautonomia: electrophysiology and response to intravenous immunoglobulin. Neurology. Feb 8 2000;54(3):770-1. [Medline].

  11. Gibbons C, Vernino S, Freeman R. Combined immunomodulation therapy in autoimmune autonomic ganglionopathy. Arch Neurol. Feb 2008;65(2):213-217.

  12. Bannister R, Mathias CJ, Polinsky R. Autonomic failure--A comparison between UK and US experience. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1988:282-8.

  13. Daniel SE. The neuropharmacology and neurochemistry of multiple system atrophy. In: Autonomic Failure: A Textbook of Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1992:564-85.

  14. Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR. Clin Auton Res. Dec 2007;17(6):334-40. [Medline].

  15. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. Apr 1996;6(2):125-6. [Medline].

  16. Mathias CJ. Disorders of the autonomic nervous system. In: Neurology in Clinical Practice. Boston, Mass: Butterworth-Heinemann; 1996:1953-81.

  17. Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: Autonomic Failure: A Textbook of Disorders of the Autonomic Nervous System. New York, NY: Oxford University Press; 1992:593-621.

  18. Quinn NP, Wenning G, Marsden CD. The Shy-Drager syndrome. What did Shy and Drager really describe?. Arch Neurol. Jul 1995;52(7):656-7. [Medline].

  19. Smit AA, Vermeulen M, Koelman JH, Wieling W. Unusual recovery from acute panautonomic neuropathy after immunoglobulin therapy. Mayo Clin Proc. Apr 1997;72(4):333-5. [Medline].

  20. Suarez GA, Fealey RD, Camilleri M, Low PA. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology. Sep 1994;44(9):1675-82. [Medline].

  21. van Ingelghem E, van Zandijcke M, Lammens M. Pure autonomic failure: a new case with clinical, biochemical, and necropsy data. J Neurol Neurosurg Psychiatry. Jun 1994;57(6):745-7. [Medline].

  22. Vernino S, Freeman R. Peripheral Autonomic Neuropathies. Continuum Lifelong Learning Neurol. Dec 2007;13(6):89-110.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.